| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Updated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile in NETs |
| 06 Nov 2026 |
8-K: Other Events
Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 |
| 06 Nov 2026 |
8-K: Other Events
Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs |
| 23 Oct 2026 |
8-K: Other Events
Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs |
| 08 Oct 2026 |
8-K: Other Events
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors |
| 01 Oct 2026 |
8-K: Other Events
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology |
| 14 Sep 2026 |
8-K: Other Events
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors |
| 08 Sep 2026 |
8-K: Other Events
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotop... |
| 03 Aug 2026 |
8-K: Other Events
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals |
| 01 Jul 2026 |
8-K: Other Events
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals |
| 01 Jun 2026 |
8-K: Other Events
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals |
| 27 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 27, 2026, Perspective Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 114,017,755 shares of common stock outstanding and entitled to vote at the Annual Meeting, 97,882... |
| 22 May 2026 |
8-K: Other Events
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalability |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Direct-to-Hospital Delivery through Integrated Isotope Production |
| 20 Apr 2026 |
8-K: Other Events
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting |
| 01 Apr 2026 |
8-K: Other Events
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals |
| 16 Mar 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026 |
| 03 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Pre-Funded Warrants to Purchase 6,598,046 Shares of Common Stock |
Loading...